- Home
- BTAI
as 03-28-2025 4:00pm EST
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 7.2M | IPO Year: | 2018 |
| Target Price: | $42.60 | AVG Volume (30 days): | 8.7M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -23.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.72 - $49.58 | Next Earning Date: | 03-27-2025 |
| Revenue: | $2,266,000 | Revenue Growth: | 64.20% |
| Revenue Growth (this year): | 105.36% | Revenue Growth (next year): | 46.93% |
Latest BioXcel Therapeutics Inc. News
BTAI Breaking Stock News: Dive into BTAI Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
4 days ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates
GlobeNewswire
4 days ago
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024
Zacks
11 days ago
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
GlobeNewswire
20 days ago
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Insider Monkey
21 days ago
Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week
GlobeNewswire
24 days ago
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Zacks
25 days ago
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?
Compare BTAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BTAI BioXcel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.